The standard treatment for hepatitis C, interferon and ribavirin, cures just 45% of those who receive it. There are now several dozen new drugs for the disease under development, and 2 were approved by the FDA in 2011: telaprevir and boceprevir. The new drugs, which directly attack the virus that causes hepatitis C with minimal impact on the human host, have raised hopes of shorter treatment times and higher cure rates. Researchers are also looking at ways of tailoring treatment to individual patients based on genetic testing.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.